Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025
Evogene (Nasdaq: EVGN) has announced the appointment of Nir Nimrodi as the new Chairperson of the Board, effective March 5, 2025. He succeeds Sarit Firon, who will continue serving as a board member. Nimrodi, who has been a board member since September 2022, brings over 20 years of international experience in life sciences, pharmaceutical, and biotechnology sectors.
The company's CEO, Ofer Haviv, will also join as a board member. Nimrodi has been involved with Evogene since 2020, initially as a special advisor before becoming a board member. The new chairman expressed commitment to unlocking shareholder value and leveraging the company's AI capabilities in drug discovery.
Evogene (Nasdaq: EVGN) ha annunciato la nomina di Nir Nimrodi come nuovo Presidente del Consiglio, con effetto dal 5 marzo 2025. Succede a Sarit Firon, che continuerà a servire come membro del consiglio. Nimrodi, che è membro del consiglio dal settembre 2022, porta con sé oltre 20 anni di esperienza internazionale nei settori delle scienze della vita, farmaceutico e biotecnologico.
Il CEO dell'azienda, Ofer Haviv, entrerà anch'esso a far parte del consiglio come membro. Nimrodi è coinvolto con Evogene dal 2020, inizialmente come consulente speciale prima di diventare membro del consiglio. Il nuovo presidente ha espresso il suo impegno a sbloccare il valore per gli azionisti e a sfruttare le capacità dell'azienda nell'IA per la scoperta di farmaci.
Evogene (Nasdaq: EVGN) ha anunciado el nombramiento de Nir Nimrodi como nuevo Presidente de la Junta, efectivo a partir del 5 de marzo de 2025. Sucede a Sarit Firon, quien continuará sirviendo como miembro de la junta. Nimrodi, quien ha sido miembro de la junta desde septiembre de 2022, aporta más de 20 años de experiencia internacional en los sectores de ciencias de la vida, farmacéutica y biotecnología.
El CEO de la empresa, Ofer Haviv, también se unirá como miembro de la junta. Nimrodi ha estado involucrado con Evogene desde 2020, inicialmente como asesor especial antes de convertirse en miembro de la junta. El nuevo presidente expresó su compromiso de desbloquear el valor para los accionistas y aprovechar las capacidades de IA de la empresa en el descubrimiento de fármacos.
Evogene (Nasdaq: EVGN)은 Nir Nimrodi를 새로운 이사회 의장으로 임명했다고 발표했습니다. 임기는 2025년 3월 5일부터 시작됩니다. 그는 이사인 Sarit Firon의 뒤를 이어 이사회 의장직을 맡게 됩니다. Nimrodi는 2022년 9월부터 이사로 재직 중이며, 생명과학, 제약 및 생명공학 분야에서 20년 이상의 국제 경험을 보유하고 있습니다.
회사의 CEO인 Ofer Haviv도 이사로 합류할 예정입니다. Nimrodi는 2020년부터 Evogene와 관련이 있으며, 처음에는 특별 고문으로 활동하다가 이후 이사로 선임되었습니다. 새로운 의장은 주주 가치를 창출하고 회사의 인공지능(AI) 기술을 활용하여 신약 개발을 추진하겠다는 의지를 밝혔습니다.
Evogene (Nasdaq: EVGN) a annoncé la nomination de Nir Nimrodi en tant que nouveau président du conseil d'administration, à compter du 5 mars 2025. Il succède à Sarit Firon, qui continuera à siéger en tant que membre du conseil. Nimrodi, membre du conseil depuis septembre 2022, apporte plus de 20 ans d'expérience internationale dans les secteurs des sciences de la vie, de la pharmacie et de la biotechnologie.
Le PDG de l'entreprise, Ofer Haviv, rejoindra également le conseil en tant que membre. Nimrodi est impliqué avec Evogene depuis 2020, d'abord en tant que conseiller spécial avant de devenir membre du conseil. Le nouveau président a exprimé son engagement à libérer la valeur pour les actionnaires et à tirer parti des capacités d'IA de l'entreprise dans la découverte de médicaments.
Evogene (Nasdaq: EVGN) hat die Ernennung von Nir Nimrodi zum neuen Vorsitzenden des Vorstands bekannt gegeben, die am 5. März 2025 in Kraft tritt. Er folgt Sarit Firon nach, die weiterhin als Vorstandsmitglied tätig sein wird. Nimrodi ist seit September 2022 Vorstandsmitglied und bringt über 20 Jahre internationale Erfahrung in den Bereichen Lebenswissenschaften, Pharmazie und Biotechnologie mit.
Der CEO des Unternehmens, Ofer Haviv, wird ebenfalls als Vorstandsmitglied beitreten. Nimrodi ist seit 2020 bei Evogene tätig, zunächst als Sonderberater, bevor er Vorstandsmitglied wurde. Der neue Vorsitzende erklärte sein Engagement, den Aktionärswert zu steigern und die KI-Fähigkeiten des Unternehmens in der Arzneimittelforschung zu nutzen.
- New Chairperson brings 20+ years of international life sciences experience
- Previous Chairperson remains on board ensuring leadership continuity
- CEO joining board strengthens corporate governance
- None.
Mr. Nir Nirmodi is Replacing Ms. Sarit Firon, who will Continue Serving as a Member of the Board
REHOVOT,
As Evogene progresses toward key milestones across its subsidiaries and programs, Mr. Nimrodi's extensive experience in scaling life sciences businesses and driving growth makes him well-suited to guide the company's next phase. His leadership will strengthen ongoing efforts and build upon the solid foundation established under Ms. Firon's tenure. Mr. Nimrodi, a member of the Evogene Board since September 2022, brings over two decades of extensive international experience across both start-ups and large global organizations within the life sciences, pharmaceutical, and biotechnology sectors.
"On behalf of Evogene, I am pleased to welcome Nir Nimrodi as the new Chairperson of the Board," said Ofer Haviv, President and CEO of Evogene. "Mr. Nimrodi has been actively engaged in Evogene's activities since 2020, initially serving as a special advisor to the Board, and subsequently as a member. With his appointment as Chairperson, I look forward to collaborating closely with him as Evogene continues on its journey. I would also like to express my gratitude to Sarit Firon for her invaluable contributions as Chairperson, and I am pleased that she will continue to support Evogene in her role as a Board member."
"I am excited about the opportunities ahead for Evogene," said Nir Nimrodi. "Several of the company's assets have the potential to create significant value for Evogene and its shareholders, and I am committed to focusing on strategies that will unlock this value starting this year. Additionally, Evogene has been leveraging advanced computational capabilities to drive product innovation for the past two decades. With the growing potential of AI, a field in which Evogene is already a natural leader, we intend to further harness our expertise to advance the drug discovery process and enhance the value we bring to this space."
In addition, Evogene's President and CEO, Mr. Ofer Haviv, will join as member of the Board, and will remain in office until the earlier of the first annual or special general meeting of shareholders following his appointment.
About Evogene Ltd.
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:
- Casterra Ag Ltd. (www.casterra.co)– developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRator AI.
- Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI;
- AgPlenus Ltd. (www.agplenus.com) -developing next generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI; and
- Biomica Ltd. (www.biomicamed.com) developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
For more information, please visit: www.evogene.com.
Forward-Looking Statements
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statements in this press release when it discusses the belief that the company's assets have the potential to create significant value for the Company and its shareholders and the success of advancing the drug discovery process. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between
Contact:
ir@evogene.com
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-announces-the-appointment-of-nir-nimrodi-as-the-new-chairperson-of-the-board-effective-march-5-2025-302394573.html
SOURCE Evogene
FAQ
When will Nir Nimrodi assume the role of Chairperson at Evogene (EVGN)?
What is Nir Nimrodi's previous experience with Evogene (EVGN)?
Who did Nir Nimrodi replace as Chairperson of Evogene (EVGN)?
What are Evogene's (EVGN) plans for AI implementation under the new leadership?
